Apollomics Inc. · NASDAQ:APLM

Apollomics — SPAC Merger (September 2022)

27 slides from Apollomics's SPAC merger presentation, September 2022

  1. Slide 1: Investor Presentation September 2022

    INVESTOR PRESENTATION S e p t e m b e r 2022

  2. Slide 2: Legal Disclaimer

    Legal Disclaimer Important Information for Investors This investor presentation (this “Presentation”) (references to which shall be deemed to include any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further enquiries) relates to

  3. Slide 3: Legal Disclaimer (contd.)

    Legal Disclaimer (contd.) No Representations and Warranties No representation, warranty or undertaking, express or implied, is made or will be given by Apollomics, Maxpro and their respective affiliates and Representatives as to the fairness, accuracy, completeness or reliability of this Presentatio

  4. Slide 4: Transaction Highlights

    Transaction Highlights deSPAC • Apollomics Inc. (“Apollomics”) and Maxpro Capital Acquisition Corp. ("JMAC") have TRANSACTION entered into a definitive business combination agreement • Transaction values Apollomics at $899M • Transaction expected to close in the first quarter of 2023 • 100% rollover

  5. Slide 5: Transaction Details

    5 Transaction Details SOURCES ($M) PRO FORMA CAPITALIZATION (M Shares, %) Redemption Rate Assumption 0% MAXIMUM Redemption Rate Assumption 0% MAXIMUM Apollomics Shareholder Equity Rollover 1 $899.0 $899.0 Apollomics Shareholder Equity Rollover 1 89.9 87.0% 89.9 94.7% JMAC public shareholders 2 10.4

  6. Slide 6: Apollomics: On a mission to discover ways to treat cancer

    Apollomics: On a mission to discover ways to treat cancer c-MET Innovative clinical-stage biotechnology company focused on discovering 1 and developing oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific VEGF/CSF1 E-selec

  7. Slide 7: Maxpro Capital Acquisition Corp. Overview

    Maxpro Capital Acquisition Corp. Overview • Maxpro Capital Acquisition Corp. (Nasdaq: JMAC) is a publicly listed special purpose acquisition company that completed a $105.05M IPO on October 13, 2021 • JMAC is sponsored by MP One Investment LLC, established by Maxpro Capital Ventures, a healthcare pr

  8. Slide 8: Seasoned Executives at Apollomics

    Seasoned Executives at Apollomics Serial Entrepreneur • Founder of Epitomics; • 28 years in oncology drug • 20+ years in global clinical Executive Chairman of Crown development development leadership: IND, Bioscience Phase 1, 2, 3, and 4 studies • 5 NDAs, 5 NCEs and 15 • 30+ years experience INDs/CT

  9. Slide 9: Seasoned Executives at JMAC

    Seasoned Executives at JMAC Senior Executive • Managing Director of Maxpro Ventures Ltd. since May 2018 • 20+ years of academic and biotech experience • Rutgers, Caltech, VivoRx, AmCyte, Celgene, Meridigen, SyneuRx Moses Chen JMAC CEO Senior Executive • Consultant at KPMG in Taiwan since February 20

  10. Slide 10: Growth: From Discovery to Clinical towards Commercial

    Growth: From Discovery to Clinical towards Commercial 2023 – 2025 Transformative Goals 2019 – 2022 Gained Momentum 2016 – 2018 › APL-101 (US-Global)*: › Series B and Series C › NDA NSCLC ex14 skip Foundation Established › APL-101: › sNDA NSCLC c-MET › Phase 1 completed › sNDA GBM c-MET fusion › Glob

  11. Slide 11: Our Pipeline

    Our Pipeline Status Drug Candidate Target Category IP Rights Mono / Combo Indications Discovery Preclinical IND Phase 1 Phase 2 Phase 3 NDA APL-101 NSCLC, GBM, c-Met Small molecule Global 1 Mono Vebreltinib other solid tumors Tumor ErbB1/2/4 positive APL-122 ErbB1/2/4 Small molecule Global 2 Mono In

  12. Slide 12: Vebreltinib (APL-101) c-Met TKI ~$10B market opportunity in NSCLC

    9 Vebreltinib (APL-101) c-Met TKI ~ $10B market opportunity in NSCLC With c-MET Dysregulation $3B market opportunity** NSCLC c-Met dysregulated Non-Small Cell Lung Cancer ("NSCLC") population • Exon-14 skip mutation (1L, 2L) ~ 6,300 patients* • c-Met amplifications, denovo ~ 2,500 patients*** • c-Me

  13. Slide 13: Regulatory Landscape of c-MET inhibitors TKI

    Regulatory Landscape of c-MET inhibitors TKI Approved c-MET inhibitor TKIs Biomarker U.S. FDA EU5 EMA JP MHLW CN NMPA Agent* Manufacturer(s) MOA Line of Therapy* (NGS) Approval Approval Approval Approval Patients with MET mutations Relapsed / Orpathys® HutchMed and AstraZeneca refractory or 1L, NSCL

  14. Slide 14: Vebreltinib: Indications for near term NDA/sNDA submissions

    Vebreltinib: 3 Indications for near term NDA/sNDA submissions Vebreltinib Global Multicohort Phase 2 – Non-Small Cell Lung cancer, Glioblastoma (“GBM”), various solid tumors with c-Met dysregulation Exon-14 skip ü Highly specific c-Met inhibitor ü Brain penetration mutated ü Safety data available fr

  15. Slide 15: Activity in a Patient with Primary NSCLC Lesions and Brain Metastasis

    Activity in a Patient with Primary NSCLC Lesions and Brain Metastasis NSCLC with c-Met amplification Targeted Small Molecule TKI Source: Yilong Wu et al, Presentation on Phase 1 Open Investigation of the Safety and Tolerability of Bozitinib Enteric Capsules in Late-Stage NSCLC with c-Met Amplificati

  16. Slide 16: Activity in a Glioblastoma Patient with c-MET Amplification

    Activity in a Glioblastoma Patient with c-MET Amplification On treatment for 2+Years • 78-yr old female, GBM since May 2015, c-Met Amplification, target lesion Lt Subependymal • Received 3 prior lines of therapies (Temodar 2015-2017, Avastin 2017-2018, Nivolumab 2018-2019) • C1D1: 04Sep2019; 2+ yr t

  17. Slide 17: Vebreltinib – Additional Indications

    Vebreltinib – Additional Indications › EGFR resistance & c-Met amplification › Other solid tumors with c-Met alterations, beyond lung & brain › Gastrointestinal cancers: colon, stomach, pancreatic, liver, cholangiocarcinoma › Renal cell cancer › Thyroid cancer › Prostate cancer › Breast cancer › Ova

  18. Slide 18: Uproleselan (APL-106) seeks to address $1.4B market for AML

    Uproleselan (APL-106) seeks to address $1.4B market for AML AML $1.4B total AML market opportunity in China** Acute Myeloid Leukemia • 1L treatment naïve AML ~ 16,400 patients* • Relapsed refractory AML ~ 12,600 patients* • AML patients unfit for chemotherapy ~ 8,800, patients* 29,400 incidence in C

  19. Slide 19: Uproleselan (APL-106) First-In-Class E-Selectin Antagonist

    Uproleselan (APL-106) First-In-Class E-Selectin Antagonist Enhances efficacy of chemotherapy & reduces mucositis (from chemotherapy) Prevents trafficking of tumor cells to the bone marrow Disrupts cell adhesion-mediated drug resistance (CAMDR) within bone marrow microenvironment Inhibits activation

  20. Slide 20: APL-106 Phase 3 Clinical trials in AML with near term readouts

    APL-106 Phase 3 Clinical trials in AML with near term readouts E-Selectin Inhibitor: first-in-class Uproleselan (APL-106) AML- Phase 3 in China ü FDA & NMPA Breakthrough Therapy Designations ü FDA Fast Track Designation 1L treatment ü AML: Significant clinical unmet needs – naïve AML high relapse ra

  21. Slide 21: Uproleselan (APL-106) Efficacy and Safety Data from US Phase 2 Trial

    Uproleselan (APL-106) Efficacy and Safety Data from US Phase 2 Trial Enhanced Efficacy Relapsed / Refractory AML Newly Diagnosed AML N=47 N=25 Response Data: 41% 72% CR/CRi Response Data: 69% 56% MRD Negative Rates Median Event Free Survival (EFS): Median Overall Survival 9.2 Months Survival Outcome

  22. Slide 22: Uproleselan Global Clinical Programs in Acute Myeloid Leukemia

    Uproleselan (APL-106) Global Clinical Programs in Acute Myeloid Leukemia GlycoMimetics Global › GMI-Sponsored Global Phase 3 trial in r/r AML; FULLY ENROLLED Studies › NCI-Sponsored Trial in Newly Diagnosed AML “Fit” for Chemo; Target interim analysis 2022 › UC Davis IST - Newly Diagnosed AML “Unfit

  23. Slide 23: Pipeline of Early Clinical and Preclinical Programs

    Pipeline of Early Clinical and Preclinical Programs IND or later stage Preclinical Preclinical • CD-40/PD-L1 bispecific monoclonal Phase 1 antibody for triggering dendritic cells to prime antigen-specific T cells • Potent MTKi against VEGFR1/2/3, • PD-L1 antibody. Partner b/cRAF, CSF1R, KIT, RET in

  24. Slide 24: APL-122: Potent panERB Inhibitor Overcomes Treatment-Resistance

    APL-122: Potent panERB Inhibitor Overcomes Treatment-Resistance In Solid Tumors & Crosses BBB to Address Brain Metastases APL-122 Effective In APL-122 Effective In Treatment-resistant gastric cancer Treatment-resistant NSCLC (T790M+) APL-122 enters brain and is retained (HER2+) N87 xenograft H1975 x

  25. Slide 25: APL-102: Potent Multitargeted kinase inhibitor

    APL-102: Potent Multitargeted kinase inhibitor against VEGFR1/2/3, b/cRAF, CSF1R, KIT, RET in Solid Tumors • Unique kinase profile with inhibition of several other key immuno-oncogenic drivers • Tumor regression in 52 PDX models, including gastric, colorectal, esophageal, and lung cancer • HCC PDX m

  26. Slide 26: Near-term Catalysts

    Near-term Catalysts 2025 2024 2023 APL-101 APL-101 • Second sNDA submission Anticipated closing of deSPAC • Expand commercial in US • Launch commercially in US transaction • File first sNDA APL-106 APL-101 APL-106 • Commercial launch for r/r/ AML • Potential for US NDA • China Phase 3 readout • sNDA

  27. Slide 27: Apollomics

    \J apollomics

Apollomics — SPAC Merger (September 2022) on 6ix